Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: Evidence of a potentially relevant species-specific interaction with diet

Journal of Lipid Research

Volumn 39, Issue 2, 1998, Pages 457-462

  Escolá Gil, Joan Carles ^a,b   Marzal Casacuberta, Àfrica ^a,b,c   Julve Gil, Josep ^a,b   Ishida, Brian Y ^d   Ordóñez Llanos, Jordi ^a,c   Chan, Lawrence ^e   González Sastre, Francesc ^a,c   Blanco Vaca, Francisco ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Institut de Recerca   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Apolipoprotein A I; Atherosclerosis; High density lipoproteins; Lecithin:cholesterol acyltransferase

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORONARY RISK; DIETARY INTAKE; ENZYME ACTIVITY; FAT INTAKE; INDUSTRIALIZATION; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; SPECIES DIFFERENCE; TRANSGENIC MOUSE;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; ARTERIOSCLEROSIS; DIET, ATHEROGENIC; GENE EXPRESSION; HUMANS; LIPOPROTEINS, HDL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; SPECIES SPECIFICITY;

EID: 0031936294     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Assmann, G., A. von Eckardstein, and H. Funke. 1993. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation. 87: III28-III34.
2. Fruchart, J. C., G. Ailhaud, and J. M. Bard. 1993. Heterogeneity of high density lipoprotein particles. Circulation. 87: III22-III27.
3. Breslow, J. L. 1996. Mouse models of atherosclerosis. Science. 272: 685-688.
4. Schultz, J. R., J. G. Verstuyft, E. L. Gong, A. V. Nichols, and E. M. Rubin. 1993. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 365: 762-764.
5. Schultz, J. R., and E. M. Rubin. 1994. The properties of HDL in genetically engineered mice. Curr. Opin. Lipidol. 5: 126-137.
6. Hennuyer, N., A. Tailleux, J. M. Caillaud, J. C. Fruchart, P. Denèfle, N. Duverger, and C Fievet. 1997. Protective effect of human apoA-II overexpression on atherogenesis in transgenic mice. Atherosclerosis. 130: S35 (abstract).
7. Warden, C. H., C. C. Hedrick, J-H. Qiao, L. W. Castellani, and A. J. Lusis. 1993. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 261: 469-471.
8. Castellani, L. W., M. Navab, B. J. Van Lenten, C. C. Hedrick, S. Y. Hama, A. M. Goto, A. M Fogelman, and A. J. Lusis. 1997. Overexpression of apolipoprotein A-II in transgenic mice converts high density lipoproteins to proinflamatory particles. J. Clin. Invest. 100: 464-474.
9. Marzal-Casacuberta, À., F. Blanco-Vaca, B. Y. Ishida, J. Julve-Gil, J. Shen, S. Calvet-Márquez, F. González-Sastre, and L. Chan. 1996. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J. Biol. Chem. 271: 6720-6728.
10. Gong, E. L., L. J. Stoltzfus, C. M. Brion, D. Murugesh, and E. M. Rubin. 1996. Contrasting in vivo effects of murine and human apolipoprotein A-II. J. Biol Chem. 271: 5984-5987.
11. Hedrick, C. C., L. W. Castellani, C. H. Warden, D. L. Puppione, and A. J. Lusis. 1993. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J. Biol. Chem. 268: 20676-20682.
12. Paigen, B., P. A. Morrow, D. Holmes, D. Mitchell, and R. A. Williams. 1987. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 68: 231-240.
13. Qiao, J-H., P-Z Xie, M. C. Fishbein, J. Kreuzer, T. A. Drake, L. L. Demer, and A. J. Lusis. 1994. Pathology of atheromatous lesions in inbred and genetically engineered mice. Arterioscler. Thromb. Vasc. Biol. 14: 1480-1497.
14. Blanco-Vaca, F., S-J. Qu, C. Fiol, H-Z Fan, Q. Pao, À. Marzal-Casacuberta, J. J. Albers, I. Hurtado, V. Gracia, X. Pintó, T. Martí, and H. J. Pownall. 1997. Molecular basis of fish-eye disease in a patient from Spain. Characterization of a novel mutation in the LCAT gene and lipid analysis of the cornea. Arterioscler. Thromb. Vasc. Biol. 17: 1382-1391.
15. Peterson, J., G. Bengtsson-Olivecrona, and T. Olivecrona. 1986. Mouse preheparin plasma contains high levels of hepatic lipase with low affinity for heparin. Biochim. Biophys. Acta. 878: 65-70.
16. Ikewaki, K., L. A. Zech, M. Kindt, H. B. Brewer, Jr., and D. J. Rader. 1995. Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. Arterioscler. Thromb. Vasc. Biol. 15: 306-312.
17. Bu, X., C. H. Warden, Y. R. Xia, C. De Meester, D. L. Puppione, S. Teruya, B. Lokensgard, S. Daneshmand, J. Brown, R. J. Gray, J. I. Rotter, and A. J. Lusis. 1994. Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition: evidence for involvement of the apolipoprotein A-II and cholesteryl ester transfer protein loci. Hum. Genet. 93: 639-650.
18. Paigen, B., B. Y. Ishida, J. Verstuyft, R. B. Winters, and D. Albee. 1990. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis. 10: 316-323.
19. 2. J. Biol. Chem. 269: 11572-11577.
20. Castro, G., L. P. Nihoul, C. Dengremont, C. de Geitère, B. Delfly, A. Tailleux, C. Fievet, N. Duverger, P. Denèfle, J. C. Fruchart, and E. M. Rubin. 1997. Cholesterol efflux, lecithin:cholesterol acyltransferase activity, and pre-β particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry. 36: 2243-2249.
21. Warden, C. H., A. Daluiski, X. Bu, D. A. Purcell-Huynh, C. De Meester, B-H. Shieh, D. L,. Puppione, R. M. Gray, G. M. Reaven, Y-D. Chen, J. I. Rotter, and A. J. Lusis. 1993. Evidence for linkage of the apolipoprotein A-II locus to plasma apolipoprotein A-II and free fatty acid levels in mice. Proc. Natl. Acad. Sci. USA. 90: 10886-10890.
22. Weng, W., and J. L. Breslow. 1996. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apoA-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc. Natl. Acad. Sci. USA. 93: 14788-14794.